Aldeyra Therapeutics Faces Class Action Lawsuits
Analysis based on 76 articles · First reported Mar 20, 2026 · Last updated Apr 20, 2026
The class action lawsuits against Aldeyra Therapeutics are expected to negatively impact its stock price and investor confidence due to allegations of misleading statements regarding drug trial results. This event highlights the risks associated with pharmaceutical companies and their clinical trial disclosures, potentially increasing scrutiny on similar firms.
Aldeyra Therapeutics is facing multiple class action lawsuits filed by Bronstein, Gewirtz & Grossman, LLC and Rosen Law Firm. The lawsuits allege that Aldeyra Therapeutics made false and/or misleading statements to investors between November 3, 2023, and March 16, 2026, concerning the inconsistent results of its reproxalap drug candidate's clinical trials. Investors who purchased Aldeyra Therapeutics securities during this period are encouraged to join the lawsuit, with a lead plaintiff deadline of May 29, 2026. The core of the complaint is that the purported positive findings from these trials were unreliable, rendering the company's statements about its business, operations, and prospects materially false and misleading.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard